Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IPSS Risk Category Intermediate-2”

32 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 32 results

Testing effectiveness (Phase 2)Study completedNCT03047993
What this trial is testing

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsBlasts 20-30 Percent of Peripheral Blood White Cells+4 more
M.D. Anderson Cancer Center 28
Not applicableStudy completedNCT00987584
What this trial is testing

Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk

Who this might be right for
Myelodysplastic Syndromes
Peter L Greenberg 13
Testing effectiveness (Phase 2)Study completedNCT01692366
What this trial is testing

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Who this might be right for
Myelofibrosis
Bristol-Myers Squibb 8
Large-scale testing (Phase 3)Active Not RecruitingNCT04576156
What this trial is testing

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Who this might be right for
Myelofibrosis
Geron Corporation 327
Testing effectiveness (Phase 2)Study completedNCT01584531
What this trial is testing

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromeMDSTrisomy 8
Traws Pharma, Inc. 82
Testing effectiveness (Phase 2)Study completedNCT01305460
What this trial is testing

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies 27
Early research (Phase 1)WithdrawnNCT02075034
What this trial is testing

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT02152956
What this trial is testing

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Who this might be right for
AML
MacroGenics 244
Testing effectiveness (Phase 2)UnknownNCT00885508
What this trial is testing

The Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 85
Large-scale testing (Phase 3)Ended earlyNCT02158936
What this trial is testing

Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Thrombocytopaenia
Novartis Pharmaceuticals 356
Large-scale testing (Phase 3)Active Not RecruitingNCT05883956
What this trial is testing

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, Chronic+1 more
Otsuka Australia Pharmaceutical Pty Ltd 13
Testing effectiveness (Phase 2)Study completedNCT02426086
What this trial is testing

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Who this might be right for
Myelofibrosis
Geron Corporation 107
Large-scale testing (Phase 3)Ended earlyNCT01437787
What this trial is testing

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 289
Testing effectiveness (Phase 2)Ended earlyNCT00666497
What this trial is testing

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Mirati Therapeutics Inc. 6
Testing effectiveness (Phase 2)WithdrawnNCT00867061
What this trial is testing

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT02010645
What this trial is testing

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT00776503
What this trial is testing

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 52
Testing effectiveness (Phase 2)Study completedNCT00531232
What this trial is testing

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia (AML)
Genzyme, a Sanofi Company 38
Testing effectiveness (Phase 2)Study completedNCT01088373
What this trial is testing

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 50
Testing effectiveness (Phase 2)Study completedNCT02016781
What this trial is testing

Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)

Who this might be right for
MDS
Medical College of Wisconsin 384
Next Page